2238 related articles for article (PubMed ID: 25935633)
21. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery.
Goossens N; Hoshida Y; Song WM; Jung M; Morel P; Nakagawa S; Zhang B; Frossard JL; Spahr L; Friedman SL; Negro F; Rubbia-Brandt L; Giostra E
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1619-1628. PubMed ID: 26492845
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
24. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
25. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
Simon TG; Henson J; Osganian S; Masia R; Chan AT; Chung RT; Corey KE
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2776-2784.e4. PubMed ID: 31077838
[TBL] [Abstract][Full Text] [Related]
26. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
27. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
Younossi ZM; Stepanova M; Rafiq N; Makhlouf H; Younoszai Z; Agrawal R; Goodman Z
Hepatology; 2011 Jun; 53(6):1874-82. PubMed ID: 21360720
[TBL] [Abstract][Full Text] [Related]
28. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
Kim D; Kim WR; Kim HJ; Therneau TM
Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
[TBL] [Abstract][Full Text] [Related]
29. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
30. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
[TBL] [Abstract][Full Text] [Related]
31. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
[TBL] [Abstract][Full Text] [Related]
32. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients.
Hirose S; Matsumoto K; Tatemichi M; Tsuruya K; Anzai K; Arase Y; Shiraishi K; Suzuki M; Ieda S; Kagawa T
PLoS One; 2020; 15(11):e0241770. PubMed ID: 33186403
[TBL] [Abstract][Full Text] [Related]
33. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
Henson JB; Simon TG; Kaplan A; Osganian S; Masia R; Corey KE
Aliment Pharmacol Ther; 2020 Apr; 51(7):728-736. PubMed ID: 32043602
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Kawada N; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):370-379. PubMed ID: 35051649
[TBL] [Abstract][Full Text] [Related]
35. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
[TBL] [Abstract][Full Text] [Related]
36. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
[TBL] [Abstract][Full Text] [Related]
37. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
Rosenblatt R; Mehta A; Snell D; Hissong E; Kierans AS; Kumar S
Dig Dis Sci; 2019 Jan; 64(1):262-268. PubMed ID: 30269271
[TBL] [Abstract][Full Text] [Related]
38. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
40. Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu IL; Brunt EM
World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
